San Francisco, CA. March 22, 2022 — The Vial Dermatology CRO announced the addition of Joseph Merola, MD, MMSc to the Vial Scientific Advisory Board. Dr. Merola will support the Vial CRO team, along with their sponsors, as they work to further advance the field of dermatology clinical research.
Launched earlier this year, under the tag line, “The CRO Built for Sponsors”, the Vial Dermatology CRO promises higher quality and faster execution of trials powered by the Vial Clinic Network of over 35 Dermatology clinical research sites across the country. The Vial Scientific Advisory Board’s leading Dermatology KOLs will service sponsors in clinical strategy, regulatory strategy, trial design and overall clinical development plan pathways.
The Vial Dermatology CRO team is led by Betsey Zbyszynski as Head of Clinical Operations, Jason Shuris as Head of Sales, Janet DuBois, MD as Medical Director, and Justin Withers as Head of Dermatology. Together, the CRO executive team brings 100+ years of combined dermatology clinical trial experience to Vial.
Dr. Merola stated, “I’m excited to work with leading dermatologists to support Vial as they continue to grow and progress the field of dermatology through technology and streamlined clinical trials.”
Dr. Merola is triple board certified in Dermatology, Internal Medicine, and Rheumatology and is actively practicing in Boston, MA. He earned his medical degree at New York University School of Medicine, followed by his Master of Medical Sciences degree at Harvard Medical School.
Dr. Merola is on the Medical Board of the National Psoriasis Foundation, the Board of the International Dermatology Outcome Measures Group, Steering Committee Member for GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), the Board of the Lupus Foundation of America and is on the Board and Founding President of the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN). Dr. Merola is also the president-elect of the Medical Dermatology Society. He is also a councilor for the International Eczema Council as well as the International Psoriasis Council.
About Vial: Vial’s mission is to run clinical trials with faster execution and higher quality in order to bring new therapies to market. Vial has over 70 employees and is based in San Francisco, California. Vial partners with Dermatologists to support their research teams and has created a network of over 35 Dermatology clinics. The Vial network has contributed to over 150 trials for many of the leading sponsors in Dermatology having run trials across common Dermatology indications (Atopic Dermatitis, Psoriasis, Vitiligo, Alopecia Areata, Rosacea, Hidradenitis Suppurativa, Prurigo Nodularis among others) as well as many Aesthetic Dermatology indications. The clinic network runs trials from Phase I through Phase IV.
